Terrance P. Coyne, Executive Vice President and CFO of Royalty Pharma plc (NASDAQ:RPRX), filed a Form 4 on August 17, 2026, disclosing the sale of Class A Ordinary Shares on August 13, 2026, pursuant to a previously established 10b5-1 trading plan.

Key Highlights

  • First sale: 9,230 Class A Ordinary Shares were disposed of at a weighted average price of $58.5864 per share, with individual transaction prices ranging from $57.99 to $58.98.
  • Second sale: 1,772 Class A Ordinary Shares were disposed of at a weighted average price of $59.1415 per share, with prices ranging from $58.98 to $59.52.
  • Plan basis: Both transactions were effected pursuant to a 10b5-1 plan adopted by Coyne on February 24, 2026.
  • Remaining indirect holdings: Following the transactions, Coyne holds 24,170 Class A Ordinary Shares through a spouse's IRA, 23,270 through an IRA, 1,450 through a spouse, and 1,500 directly.
  • Exchangeable interests: Coyne and family vehicles also hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 6,448,180 Class A Ordinary Shares, and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 1,788,777 Class A Ordinary Shares, the latter subject to vesting conditions.

Coyne's August 2026 Share Dispositions and Beneficial Ownership at Royalty Pharma

According to the filing, Terrance P. Coyne, serving as EVP and CFO of Royalty Pharma plc, sold a total of 11,002 Class A Ordinary Shares on August 13, 2026. Both sales were made indirectly through TPC RP EPA1 LLC, a vehicle associated with the reporting person. The filing indicates the transactions were carried out under a 10b5-1 plan Coyne adopted on February 24, 2026, which is designed to satisfy the affirmative defense conditions of Rule 10b5-1(c).

The first block of 9,230 shares was sold at a weighted average price of $58.5864, in multiple transactions at prices ranging from $57.99 to $58.98. The second block of 1,772 shares was sold at a weighted average price of $59.1415, in multiple transactions at prices ranging from $58.98 to $59.52. Following both sales, the TPC RP EPA1 LLC position reached zero shares, according to the filing.

The filing also discloses that Coyne retains other beneficial interests: 1,500 shares held directly, 23,270 shares through an IRA, 24,170 shares through a spouse's IRA, and 1,450 shares through a spouse. In addition, the remarks section states that Coyne and family vehicles hold limited partnership interests exchangeable into 6,448,180 Class A Ordinary Shares, as well as Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 1,788,777 Class A Ordinary Shares, with the Class E shares noted as subject to vesting conditions.

What Was Disclosed

The filing reports two dispositions of Class A Ordinary Shares by Royalty Pharma's CFO on August 13, 2026, both executed through TPC RP EPA1 LLC under a 10b5-1 plan, along with a summary of the reporting person's remaining direct and indirect beneficial ownership positions.